<DOC>
	<DOCNO>NCT00259974</DOCNO>
	<brief_summary>Polyneuropathy associate anti-MAG monoclonal IgM gammopathy responsive mainly sensory deficit predominantly male , age 40-70 year . Significantly high serum anti-MAG antibody link demyelinate feature peripheral nerves.Rituximab , anti-CD 20 monoclonal antibody new drug reduce B-lymphocytes . This study test safety efficacy rituximab treatment patient anti-MAG polyneuropathy .</brief_summary>
	<brief_title>RIMAG Study : Trial Rituximab Versus Placebo Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy</brief_title>
	<detailed_description>Acting polyneuropathy treatment reference today ( see supra ) , test double-knowledge versus placebo justify . Acting chronic polyneuropathy , clinical evaluation must lead one one year period . Acting sensitive polyneuropathy await benefit IMPROVEMENT OF CLINICAL SIGNS , principal criterion sensitive score addition validate chronic sensitive polyneuropathies immunodeficiency syndrome . The patient answer criterion inclusion none inclusion ( see V-2 ) randomize 2 group : first group receive perfusion IV rituximab amount 375 mg/m2 body surface , per week , 4 week ( see VII-3 ) ; second group receive 4 perfusion IV placebo accord method ' . The evaluation ( see VI-1 ) carry time randomization , repeat 3 month , 6 month , 9 month 1 year .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>IgM monoclonal gammopathy AntiMAG antibody titer &gt; 1.1000 BTU ( ELISA ) Worsening polyneuropathy INCAT score &gt; 4 Informed consent Severe comorbidity Other concurrent cause polyneuropathy Concurrent immunosuppressive therapy ( washout &gt; 3 month ) Previous treatment rituximab Lymphoproliferative disease indicate immunosuppressive treatment Unability followup Previous document sideeffects component involve tested drug White cell count &lt; 1500/mm3 platelet count &lt; 75.000/mm3 Patient law</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Anti-MAG monoclonal gammopathy</keyword>
	<keyword>Polyneuropathy</keyword>
	<keyword>Rituximab</keyword>
</DOC>